









No causal treatment for chemotherapy-induced peripheral neuropathy (CIPN) is known. Therefore,
there is an urgent need to develop a therapy for CIPN. Only scarce clinical data are available
concerning magnetic field therapy (MFT) in this context. We conducted a unicentric, randomized,
double-blind, placebo-controlled phase-III trial of an MFT device versus placebo. In this study, we
randomized 44 patients with CIPN to two treatment groups, where 21 patients were treated with
MFT (Group 1) and 23 patients received placebo (Group 2). We evaluated the efficacy of MFT at
baseline (T1), after 3 weeks of study treatment (T2), and after 3 months of study treatment (T3). The
primary endpoint was nerve conduction velocity (NCV), while secondary endpoints were the
Common Toxicity Criteria (CTCAE) score and the Pain Detect End Score at T3. Seventeen of
the patients in Group 1 and 14 patients in Group 2 completed the respective study treatment. The
primary endpoint, significant improvement of NCV at T3, was achieved by MFT (P¼ 0.015),
particularly for sensory neurotoxicity of the peroneal nerve. Also, in respect to the secondary
endpoints, significant improvement (P¼ 0.04) was achieved in terms of the patients’ subjectively
perceived neurotoxicity (CTCAE score), but not of neuropathic pain (P¼ 0.11). From data in the
randomized study presented here, a positive effect on the reduction of neurotoxicity can be assumed
for the MFT device. Patients with sensory neurotoxicity in the lower limbs, especially, should
therefore be offered this therapy. Bioelectromagnetics. 38:85–94, 2017.
© 2016 The Authors. Bioelectromagnetics published by Wiley Periodicals, Inc.
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INTRODUCTION
Chemotherapy-induced peripheral neuropathy
(CIPN) has gradually emerged as a significant long-
term toxicity in cancer patients [Hausheer et al., 2008;
Wolf et al., 2008]. In this context, it particularly
affects patients with colon, bronchial, breast, and
ovarian carcinoma, as well as non-Hodgkin lympho-
mata, head and neck tumors, and germ cell cancers,
because these tumors are primarily treated with
platinum compounds, taxanes, or vinca alkaloids
[Grisold et al., 2012]. While vinca alkaloids result in
axonal degeneration, platinum compounds cause
demyelination of peripheral nerves [Sahenk et al.,
1987; Shemesh and Spira, 2010]. In contrast, data
from an electrophysiological study demonstrated that
only the sensory compound was affected by CIPN,
with a decrease in nerve conduction velocity (NCV),
suggesting significant reduction in the number of fast
fibers and a corresponding increase in the number of
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slow-conducting ones, although the total amount of
active myelinated fibers was thought to be unchanged
[Leandri et al., 2012].
Since CIPN is not only painful for patients,
impairing their quality of life, and can even result in
disability with all the respective socio-economic con-
sequences, effective treatment is needed. Neither
preventive measures nor supportive measures and drug
therapies have addressed this necessity so far [Hersh-
man et al., 2014; Loprinzi et al., 2014]. For this reason,
establishing a biophysical treatment also seems advis-
able. Initial positive results were achieved by our own
study group using low-frequency (50–100Hz) alternat-
ing current therapy. The number of patients suffering
from II8 and III8 sensory CIPN was reduced by 20%
during 3–4 weeks of treatment [Geiger and Rick,
2007]. Additionally, Geiger et al. [2015] were the first
to demonstrate the possible efficiency of using low-
frequency magnetic field therapy (MFT) in patients
with CIPN. A considerably larger body of data on
MFT is available for the treatment of diabetic neuropa-
thy. Particularly positive influences were found for
neuropathic pain in diabetic patients using MFT
[Weintraub et al., 2003; Mert et al., 2010].
The objective of this prospective, randomized,
placebo-controlled phase-III study was to measure the




Eligible patients were aged 18 years, with
histologically confirmed carcinoma and a history of
potentially neurotoxic chemotherapy. The inclusion
criteria of the study were: CIPN I8–IV8, good patient
compliance, life expectancy of more than 6 months.
All patients were provided with information regarding
the planned treatment and gave their written consent.
The exclusion criteria were defined as: acute infec-
tion, diabetes mellitus, pernicious anemia, spinal canal
stenosis, insufficiently controlled arterial hyperten-
sion, metal implants in close proximity to the area to
be treated, pacemakers, acute cardiovascular illnesses,
thromboses or arterial occlusive diseases in the area
of the extremity to be treated, newly implemented or
modified pain management due to CIPN within 1
week before study enrollment or during the study, and
absence of written informed consent from the patient.
Study Design
The study was a unicentric, randomized, double-
blind, placebo-controlled, phase-III trial of an MFT
device versus placebo. The trial conformed to the
Declaration of Helsinki and the Good Clinical Practice
guidelines, and it was approved by the independent
Ethics Commission of the German Medical Associa-
tion. Patients were randomly assigned at a 1:1 ratio to
receive MFT or the placebo. Randomization, study
management, and data analysis were performed by the
Clinical Trials Office at the Medical Center of Cancer
Rehabilitation (Klinik Reinhardsh€ohe, Bad Wildungen,
Germany). The authors and the sponsor co-developed
the trial protocol, and all had access to the primary
data after study completion. Data were collected and
analyzed only by the principal investigator. Decisions
regarding the content of this article were made by the
principal investigator and other authors. Furthermore,
all authors vouch for the accuracy of the data.
MAGCELL Device
For patient treatment, the magnetic cell stimula-
tor MAGCELL MICROCIRC (PHYSIOMED ELEK-
TROMEDIZIN, Schnaittach, Germany) was used,
which is a hand-held and battery-powered device. No
coils were used for field generation. Instead, four
458 segments of a special magnetic material were
mounted symmetrically on a pivoting disc (diameter:
6 cm, area: 28 cm2). The magnetically active disc area
was fully available for treatment. Disc rotation was
regulated in increments of 2Hz to produce frequen-
cies in the range from 4 to 12Hz. At the end of the
therapeutic cycle (5min), the device stopped automat-
ically. Neither cycle length nor frequency could be
changed manually. However, the device could be
switched off at any time, if necessary.
Rotation of the magnetic disc was provided by a
microprocessor-controlled DC motor. Quasi-sinusoidal
magnetic fields were obtained in this way. On the
device surface, a magnetic flux density of 420mT
(peak-to-peak) was measured by means of the MP-U
device; at a tissue depth of 1 cm, the flux density was
still 105mT. Reduction of the flux density with
increasing depth was of no concern, since the thera-
peutic target in this study were nerves located close to
the surface (no more than 1mm below the surface).
Relevant parameters for the biomedical activity
of magnetic fields varying over time are the electric
field strength and, in particular, the electric current
density induced in the therapeutically relevant target
tissue. Computational examples based on the law of
induction are given, for example, by Bassen et al.
[1992] or Schimmelpfeng and Dertinger [1997]. Using
the diameter of the magnetically active area (6 cm),
the flux density on the device surface (420mT), and
the average frequency of the therapeutic cycle (8Hz),
an induced field strength of 320mV/m can be
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calculated. This quantity is of advantage for modeling
effects in electrically non-conducting tissues. Multipli-
cation of the field strength with specific electric
conductivity of the target tissue (nerve) yields the
electric current density. Electric conductivity can be
computed from electric resistance data measured in
various tissues [Rush et al., 1963; Geddes and Baker,
1967]. A value of 0.17 S/m for nerve tissue results in a
current density of 55mA/m2. Internationally,
responses to current densities exceeding 10mA/m2 are
qualified as well established. Since the MAGCELL
produces more than the quintuple of this density, the
apparatus can be considered therapeutically effective.
Biophysical mechanisms of action with special refer-
ence to this study are dealt with in the discussion.
Finally, from current density and exposure time
per session (300 s), the energy dose can be calculated.
Assuming that only the dose induced in a small
volume (1 cm3) around the target nerve is relevant for
our study, the effective figure is calculated to amount
to 54mJ/cm3. This figure is several orders of magni-
tude lower than the level of “natural” (e.g., thermal)
energies present in biological matter. An explanation
as to why such extremely low electromagnetic ener-
gies are effective at all is offered by the so-called
“Stochastic Resonance” effect published earlier in this
journal [Kruglikov and Dertinger, 1994].
MAGCELL placebo devices were identical to
the therapy instruments, except that the magnetic
sectors were replaced by non-magnetic elements.
Neither the patient nor the doctor in attendance could
distinguish between the two types.
Study Endpoints, Treatment, and Assessments
The working hypothesis was that MAGCELL is
superior to placebo in the improvement of NCV.
Therefore, the primary endpoint was the NCV at the
end of the study (T3). Secondary endpoints included
the Common Toxicity Criteria (CTCAE) score and
Pain Detect End Score, also at T3.
Each patient received MFT twice daily, in the
morning and in the evening, with temporally varying
intensity (4–12Hz, 420mT) for 5min separately for
each affected extremity. The patient was asked to
lightly rest each affected palm and/or sole, one at a
time, on the device. In addition, all patients were
given one occupational therapy treatment in the area
of the affected extremity three times a week.
At the beginning and at the end of the therapy, an
assessment was made in terms of the study endpoints,
and a thorough physical examination was performed,
including the neurological status and a detailed survey,
to prevent treatment side effects. According to the
neurological examination, the severity of CIPN was
recorded, based on the CTCAE form from the National
Cancer Institute (NCI) prior to and after treatment.
Moreover, at the beginning and at the end of the
therapy, NCV (Neurowerk, Sigma Medizin-Technik,
Gelenau, Germany) was measured as previously de-
scribed [Wiederholt, 1969; Bock and Liesegang, 1972].
The neuropathic pain was evaluated using the painDE-
TECT questionnaire (German Research Network on
Neuropathic Pain).
Statistical Analysis and Data Handling
All patient data were recorded using standard-
ized documentation. Data collected in this way were
computerized for further evaluation, and assessed
using a commercially available statistics program
(Statistika, StatSoft, Hamburg, Germany). The work-
ing hypotheses were statistically significant improve-
ments in NCV and reduction of CIPN as measured by
the CTCAE and painDETECT questionnaires after 3
months of study treatment. A two-sided test was
performed, and a P-value <0.05 was considered
statistically significant. The level was set at a¼ 5%,
power 1–b¼ 80%. For the study, 22 patients per
group were taken as the random sample size for the
primary outcome. The expected dropout rate
(5%¼ 2.2 participants) was based on a pilot trial and
general experience with short intervention periods
[Geiger et al., 2015]. The total random sample size
was thus n¼ 44 patients. Differences recorded
between the two groups were represented as box and
whisker plots based on mean value and standard
deviation, minimum and maximum, and checked for
normal distribution by the Shapiro Wilk test. With
regard to the CTCAE scale, the painDETECT ques-
tionnaire, and the NCV, the two groups were com-
pared using the Mann and Whitney test, while the
Wilcoxon test for paired differences was used for
comparison of the values from the initial examinations
with those from the final examinations.
The study was devised in compliance with
the “intent-to-treat” principle, that is, all protocol-
compliant patients included in the study were included
in the final analysis.
RESULTS
Study Population
From May 2010 to March 2012, 44 patients, of
which 31 were women (70%) and 13 men (30%),
suffering from CIPN were randomized, with 21 patients
being assigned to Group 1 (MFT) and 23 patients to
Group 2 (placebo). Three weeks after study enrollment
(T2), 20 and 21 patients were evaluable in Group 1 and
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Group 2, respectively. By the end of the study (T3), a
further 10 patients, 3 in Group 1 and 7 patients in Group
2, had quit the study. Thus, only 17 patients with MFT
and 14 patients with the placebo completed the study
treatment (Fig. 1). The median age of the groups was
58 years (range: 28–73 years in Group 1 and 43–73
years in Group 2). Before study enrollment, all patients
had received potentially neurotoxic chemotherapy as
part of their cancer treatment. More patients in Group 1
had been treated with platinum-based chemotherapy
than had been in Group 2. The median number of
chemotherapy cycles received by the patients was six in
both groups (range: 2–12 cycles in Group 1, and 6–16
cycles in Group 2), and the median period between the
last chemotherapy and the beginning of the study
treatment was 91 days (range: 14–774 days) in Group 1,
and 85 days (range: 13–1380 days) in Group 2. The
median study therapy duration per patient was 103 days
(range: 19–186 days) in Group 1, and 123 days (range:
11–276 days) in Group 2. Cancer diagnoses were not
balanced well, either. Nearly half of the patients in
Group 2 suffered from breast cancer, as opposed to one-
third of the patients in Group 1. All differences were
statistically insignificant (Table 1).
Neurological Outcomes
Both in Group 1 (MFT arm) and Group 2
(placebo arm), neuropathic complaints abated during
Fig. 1. Study populations. MFT, magnetic field therapy; T1, study entry; T2, 3 weeks of study
treatment; T3, 3 months of study treatment.
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the study, in terms of subjective perception docu-
mented in the CTCAE questionnaire. This effect is
particularly noticeable for all neurological qualities in
the context of III8 toxicities. Consequently, reduction
occurred from III8 to I8 or II8 toxicities and even to
complete disappearance of neural injury (Table 2).
The total CTCAE score was also significantly reduced
in both groups. However, these differences were not
significant in a comparison of the two groups.
Nevertheless, a statistically significant difference at
T2 (4 points in Group 1 and 7.5 points in Group 2;
P¼ 0.042) and T3 (2 points in Group 1 and 3 points in
Group 2; P¼ 0.04) measurements between the MFT
and placebo groups was established (Fig. 2).
In the measurement of sensory neuropathy of the
ulnar nerve at T1–T2, a statistically significant improve-
ment of the mean NCV from 49m/s (range: 26–64
m/s) to 55m/s (range: 32–72m/s) was found. In
comparison to the placebo group, this effect was also
statistically significant (P¼ 0.021). While in the MFT
group there was no significant difference between
times T2 and T3, in the placebo group a significant
improvement from 50m/s (range: 45–56m/s) at T2 to
58m/s (range: 48–68m/s) at T3 was measured
(P¼ 0.013). However, compared to the MFT group
this difference was not significant. Neither was there
any significant difference between individual times in a
comparison of the two groups (Fig. 3a).
The NCV of the peroneal nerve displayed
pathological values for both groups at all three
measuring times. The sensory neuropathy of the
peroneal nerve also displayed significant improvement
in the mean NCV of the patients in Group 1. While at
T1 a mean value of only 18m/s (range: 10–25m/s)
was measured, at T2 a mean NCV of 28m/s (range:
12–51m/s) was recorded. This difference just fell
short of being significant (P¼ 0.084). At the end of
the study (T3), further significant improvement
(P¼ 0.039) in the NCV to 40m/s (range: 18–53m/s)
compared to T2 was recorded. There were no signifi-
cant differences between measuring times in the
placebo group. In a comparison of the two study
groups, there were no significant differences between
the measuring times, either. There was only one
significant difference between the two groups at time
T3 in favor of the MFT patients (P¼ 0.015) (Fig. 3b).
Based on the Pain Detect End Scores, during the
study period significant abatement in neuropathic pain
occurred in Group 1 between T1 and T2, amounting to
a decrease from 16 points (range: 7–28 points) to 11
points (range: 2–21 points) (P¼ 0.001) and between
T1 and T3 to just 6 points (range: 0–18 points)
(P¼ 0.001). However, in the placebo group similarly
significant abatement in neuropathic pain occurred
between T1 or T2 and T3, from 13 points (range: 9–14
points) and 12 points (range: 4–25 points) down to 3
points (range: 1–14 points) (P¼ 0.001 or 0.002).
Neither these differences within the groups nor the
score for the individual measuring times differed
significantly between the study arms (Fig. 4).
DISCUSSION
This study is the first to subject MFT to
double-blind testing in a randomized placebo-con-
trolled manner in patients with CIPN. Furthermore,
it is the first trial to show a significant benefit of a
therapeutic intervention for CIPN compared to the
placebo. The novel finding is that MFT is the only
non-pharmacological intervention offering a signifi-
cant benefit in the treatment of patients with CIPN.
The primary study endpoint, significant improve-
ment of NCV, was achieved by MFT at the end of
the study (T3). Also, in respect to the secondary
endpoint, a significant improvement in the patients’
subjectively perceived neurotoxicity (CTCAE score)










Male 6 (29) 7 (30)
Female 15 (71) 16 (70)
Diagnosis
Lymphoma 4 (19) 2 (9)
Breast 7 (33) 11 (48)
Ovarian 4 (19) 2 (9)
Colorectal 5 (24) 5 (22)





Platinum 10 (48) 6 (26)
Taxane 10 (48) 11 (48)
Vinca alkaloids 3 (14) 3 (13)
Other 9 (43) 8 (35)




Duration of study treatment (days)
Median 103 123
Range 19–186 11–276
MFT, magnetic field therapy; n, number.
All differences were not statistically significant with P> 0.05.
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was achieved by MFT. The second secondary
endpoint, improvement of neuropathic pain (Pain
Detect End Score), was not achieved.
Benefits of the study can be found in the largely
well-balanced patient characteristics, whereby patients
in the MFT arm had received more platinum-based
therapy and were treated more briefly with MFT. The
positive effect of MFT might have been more
pronounced if the patient characteristics had been
distributed more evenly. Moreover, pathological
values were found for NCV, particularly for the
peroneal nerve, which proves that the measuring
method selected in this case produced reliable values.
In this connection, it was established that MFT has a
particularly positive impact when CIPN is more
strongly manifested. This effect might be an explana-
tion for the perceptible decline in III8 toxicities, as
illustrated in Table 2.
However, reduction in neurotoxicity occurs not
only in the MFT arm, but also in the placebo arm.
The most plausible explanation for this is that during
the study, both arms were subject to spontaneous
regeneration. In addition, particularly in respect to the
patients’ subjective assessment of neurotoxicity and
neuropathic pain, a psychogenic effect of the therapy
as well as of the placebo device cannot be excluded.
However, a possible psychogenic effect cannot have
influenced the NCV, which is regarded as a strong
objective parameter. The improvement at this point
must most likely be interpreted as a result of regenera-
tion of nerve fibers by MFT. The particularly strong
manifestation of this effect in areas of the peripheral
nerves of the lower limbs may be attributable to the
fact that in our study population, the crural nerves
were affected particularly strongly by neurotoxicity,
and at the beginning of the study very low mean
values for NCV were recorded. In this situation, MFT
seems to have a particularly positive effect and to be
more effective than for only minor NCV reductions.
To further support these results, reference is
made to the previous pilot study conducted by our
study group, which formed the basis for planning the
randomized study presented here. Results of the pilot
study indicate a trend to positive effect on CIPN in
terms of most neurophysiological qualities, although
the therapy was conducted for only 3–4 weeks.
TABLE 2. Neurotoxicity in Accordance With CTCAE in Group 1 and Group 2 at T1–T3


















T1 0 0 3/14 2/9 7/33 10/44 11/52 11/48
T2 2/10 2/10 7/35 5/24 8/40 10/48 3/15 4/19
T3 10/60 1/7 5/29 11/79 2/11 1/7 0 1/7
Peripheral motor
neuropathy
T1 2/9 0 3/14 5/22 10/48 8/35 6/29 10/44
T2 13/65 6/29 2/10 7/33 5/25 7/33 0 1/5
T3 11/65 2/14 6/35 10/71 0 2/14 0 0
Peripheral sensory
neuropathy
T1 2/10 1/4 3/14 1/4 8/38 8/34 8/38 13/56
T2 1/5 2/9 9/45 7/33 8/40 8/38 2/10 4/19
T3 4/23 3/21 12/71 10/71 1/6 1/7 0 0
Myopathy
T1 6/28 3/13 6/28 5/22 6/28 9/39 3/14 6/26
T2 16/80 6/29 1/5 8/38 3/15 7/33 0 0
T3 14/82 10/71 3/17 3/21 0 1/7 0 0
Myalgia
T1 7/33 8/35 10/47 3/13 4/19 7/30 0 5/22
T2 17/85 13/62 2/10 5/24 1/5 3/14 0 0
T3 17/100 14/100 0 0 0 0 0 0
Neuropathic pain
T1 1/5 3/13 6/28 0 8/38 11/48 6/28 9/39
T2 3/15 2/10 13/65 5/24 4/20 12/57 0 2/9
T3 11/65 8/57 5/29 4/28 1/6 2/14 0 0
CTCAE, common terminology criteria for adverse events; pts, patients.
T1: Group 1¼ 21 pts., Group 2¼ 23 pts.; T2: Group 1¼ 20 pts., Group 2¼ 21 pts.; T3: Group 1¼ 17 pts., Group 2¼ 14 pts.
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Components of sensory ataxia and neuropathy showed
particular improvement, as CIPN predominantly con-
sists of sensory, rather than motor, symptoms. Evalua-
tion of neuropathic pain, which was documented
using a visual analogue scale and the painDETECT
questionnaire, demonstrated low and non-significant
alleviation of symptoms. When comparing the situa-
tion before and after therapy, the sensory neurography
showed a statistically significant increase of the NCV
on the sural nerve, which could represent an objectifi-
able effect of MFT [Geiger et al., 2015]. Ultimately,
data of the pilot study match those of the randomized
study and can thus be regarded as confirmed. In the
pilot study, a therapeutic effect could also be docu-
mented within just 3 weeks, which in the randomized
study proved to be significant for the NCV of
the ulnar nerve and a trend for the peroneal nerve
(Fig. 3a and b).
The clinical practice guideline of the Ameri-
can Society of Clinical Oncology published in
June 2014 describes limited evidence presented by
recent studies [Hershman et al., 2014]. Only a pilot
study of 16 patients with refractory CIPN had,
when testing a cutaneous electrostimulation device,
shown a statistically significant improvement in
pain scores (59% reduction at 10 days, P< 0.001)
[Smith et al., 2010]. However, another very small,
randomized study, not published as a full paper
until now, comprising 14 patients, failed to demon-
strate a benefit of electrostimulation therapy [Camp-
bell et al., 2013].
Biophysical Mechanisms of Action
As outlined in Patients and Methods (see de-
scription of the MAGCELL device above), the electric
current density induced in the target tissue by the
magnetic field is accepted to be the relevant parameter
to correlate with biologic response. However, since
the device uses rotating permanent magnets to gener-
ate a temporally varying magnetic field, the magnetic
vector itself could possibly contribute to the therapeu-
tic effect. This question was addressed in a study
Fig. 2. CTCAE scores in Group 1 and Group 2. In both groups, there are significant differences
betweenT1 and T2, betweenT1 and T3, and betweenT2 and T3.Within the groups, these differ-
ences are not significant in a comparison of the two arms. Furthermore, significant differences
between the MFT and placebo groups at T2 and T3, but not at T1, were established. CTCAE,
common terminology criteria for adverse events; MFT, magnetic field therapy; T1, baseline (at
study enrollment), T2, after 3 weeks of study treatment; T3, after 3 months of study treatment;
Z, standard deviation.
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Fig. 3. a: Sensory neurography on ulnar nerve. In the MFT group, a significant difference was
established betweenT1and T2, andbetweenT1and T3.Therewere also significant differencesbe-
tweenT1and T3, and betweenT2 and T3 in the placebo group. In the comparison between the two
groups, therewasasignificantdifferenceonlybetweenT1andT2.b:Sensoryneurographyonpero-
neal nerve. A significant difference was established betweenT1 and T3, and betweenT2 and T3,
only in the MFT group, but not in the placebogroup. In the intergroup comparison, a significant dif-
ferencewasestablished onlyat T3.MFT, magnetic field therapy;T1, baseline (at studyenrollment),
T2, after 3weeksofstudy treatment;T3, after 3monthsofstudy treatment; Z, standarddeviation.
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conducted at the Institute of Anatomy, Technical
University of Dresden [Funk et al., 2014], where
stimulation of blood flow in fingers of volunteers by
the MAGCELL was investigated. A strong effect was
observed after a single local treatment, leading to 37%
increase in blood flow above the control figures
(P< 0.001). When the device was shut off (only the
permanent magnetic field remaining active), an in-
crease by only 14% was achieved. Although this
effect, which is due to the Lorentzian force acting on
ions in the flowing blood, was not statistically
significant, its contribution to blood flow stimulation
still cannot be fully ruled out. Clarification of this
question would require analogous investigations using
low-frequency currents applied via electrodes, which
were beyond the scope of our study. However, a study
in healthy volunteers aiming at investigating elec-
trode-based stimulation of microcirculation in skin by
TENS (Trancutaneous Electrical Nerve Stimulation)
resulted in 40% increase of microcirculation
[Wikstr€om et al., 1999], which is almost identical to
the figure of 37% achieved with the MAGCELL
device. This result argues against a significant contri-
bution of the magnetic vector. In addition to increased
blood flow, Funk et al. [2014] observed rapid onset
and significant enhancement of NO radical release
(43%, P< 0.001) when cultured HUVEC cells were
treated with the MAGCELL. This can explain the
increase in blood flow in terms of mediator-induced
dilatation of micro-vessels.
Among the biological mechanisms promoting
the clinical effects presented in this study, nerve
regeneration is of particular significance. Neurite
outgrowth, elongation, and other parameters have
been investigated in several systems under exposure
to electrical DC fields and various pulsating electro-
magnetic fields [Macias et al., 2000]. However, it is
questionable whether these results also apply to nerve
fibers damaged by cytostatic agents. On the other
hand, potent stimulation of microcirculation by the
Fig. 4. Pain detect end score. A significant difference in the reduction of neuropathic pain
was established betweenT1 and T3 in both study groups. In addition, there is a significant dif-
ference between T1 and T2 in the MFT group, and between T2 and T3 in the placebo group.
The differences between the two groups were not statistically significant. MFT, magnetic field
therapy; T1, baseline (at study enrollment), T2, after 3 weeks of study treatment; T3, after
3 months of study treatment; Z, standard deviation.
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MAGCELL [Funk et al., 2014] may effectively
support regeneration of the damaged nerve fibers,
since it improves the physiological and nutritional
status of the embedding tissue.The high magnetic flux
density provided by the MAGCELL enables even
treatment of targets located at a depth of up to 1 cm. A
recent clinical study on patients with knee joint
osteoarthritis showed benefits from this [Wuschech
et al., 2015]. Pain, stiffness, and disability in daily
activities improved over the placebo group to a
statistically highly significant extent.
In summary, the MAGCELL combines several
outstanding features such as: electromagnetic properties
superior to other devices, despite hand-held design;
battery-powered and microprocessor-controlled opera-
tion; and action unhampered by clothes and bandages.
Statistically significant effects and the therapeutic
benefit from using this device are well documented in
studies by Funk et al. [2014] and Wuschech et al.
[2015]. Based on significant therapeutic effects ob-
served in the present study, patients with sensory
neuro-toxicities should be offered this therapy.
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